Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics

Thrombosis Research

Volumn 137, Issue , 2016, Pages 178-183

  Testa, Sophie ^a   Tripodi, Armando ^b   Legnani, Cristina ^c   Pengo, Vittorio ^d   Abbate, Rosanna ^e   Dellanoce, Claudia ^a   Carraro, Paolo ^d   Salomone, Luisa ^c   Paniccia, Rita ^e   Paoletti, Oriana ^a   Poli, Daniela ^d   Palareti, Gualtiero ^f  

^a CREMONA HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^e University Hospital   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Anti FXa; Creatinine clearance; Dilute thrombin time; DOAC; Inter individual variability; Intra individual variability

Indexed keywords

APIXABAN; CREATININE; DABIGATRAN; RIVAROXABAN; ANTICOAGULANT AGENT;

AGED; ARTICLE; ATRIAL FIBRILLATION; BLOOD SAMPLING; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBIN TIME; BIOAVAILABILITY; BLOOD; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECTS; GLOMERULUS FILTRATION RATE; ITALY; ORAL DRUG ADMINISTRATION; PREVALENCE; REPRODUCIBILITY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; THROMBOEMBOLISM; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BIOLOGICAL AVAILABILITY; COMORBIDITY; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; ITALY; MALE; PREVALENCE; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 84952637636     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2015.12.001     Document Type: Article

References (19)

1. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, J. Pogue, P.A. Reilly, E. Themeles, J. Varrone, S. Wang, M. Alings, D. Xavier, J. Zhu, R. Diaz, B.S. Lewis, H. Darius, H.C. Diener, C.D. Joyner, L. Wallentin, and RE-LY Steering Committee and Investigators Dabigatran versus warfarin in patients with atrial fibrillation N. Engl. J. Med. 361 2009 1139 1151
2. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, W. Hacke, G. Breithardt, J.L. Halperin, G.J. Hankey, J.P. Piccini, R.C. Becker, C.C. Nessel, J.F. Paolini, S.D. Berkowitz, K.A. Fox, R.M. Califf, and R.O.C.K.E.T.A.F. Investigators Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N. Engl. J. Med. 365 2011 883 891
3. C.B. Granger, J.H. Alexander, J.J. McMurray, R.D. Lopes, E.M. Hylek, M. Hanna, H.R. Al-Khalidi, J. Ansell, D. Atar, A. Avezum, M.C. Bahit, R. Diaz, J.D. Easton, J.A. Ezekowitz, G. Flaker, D. Garcia, M. Geraldes, B.J. Gersh, S. Golitsyn, S. Goto, A.G. Hermosillo, S.H. Hohnloser, J. Horowitz, P. Mohan, P. Jansky, B.S. Lewis, J.L. Lopez-Sendon, P. Pais, A. Parkhomenko, F.W. Verheugt, J. Zhu, L. Wallentin, and ARISTOTLE Committees and Investigators Apixaban versus warfarin in patients with atrial fibrillation N. Engl. J. Med. 365 2011 981 992
4. R.P. Giugliano, C.T. Ruff, E. Braunwald, S.A. Murphy, S.D. Wiviott, J.L. Halperin, A.L. Waldo, M.D. Ezekowitz, J.I. Weitz, J. Špinar, W. Ruzyllo, M. Ruda, Y. Koretsune, J. Betcher, M. Shi, L.T. Grip, S.P. Patel, I. Patel, J.J. Hanyok, M. Mercuri, E.M. Antman, and ENGAGE AF-TIMI 48 investigators Edoxaban versus warfarin in patients with atrial fibrillation N. Engl. J. Med. 369 2013 2093 2104
5. M.M. Samama, C. Guinet, L. Le Flem, E. Ninin, and J.M. Debue Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study J. Thromb. Thrombolysis 35 2013 140 146
6. T. Baglin The role of the laboratory in treatment with new oral anticoagulants Br. J. Haematol. 163 2013 160 167
7. E.M. Hawes, A.M. Deal, D. Funk-Adcock, R. Gosselin, C. Jeanneret, A.M. Cook, J.M. Taylor, H.C. Whinna, A.M. Winkler, and S. Moll Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels J. Thromb. Haemost. 11 2013 1493 1502
8. D. Kubitza, A. Roth, M. Becka, A. Alatrach, A. Halabi, H. Hinrichsen, and W. Mueck Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct factor Xa inhibitor Br. J. Clin. Pharmacol. 76 2013 89 98 (Erratum in: Br J Clin Pharmacol. 2013;76:489)
9. I.Y. Gong, and R.B. Kim Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban and apixaban Can. J. Cardiol. 29 2013 S24 S33
10. V. Pengo, L. Crippa, A. Falanga, G. Finazzi, Marongiu, G. Palareti, D. Poli, S. Testa, E. Tiraferri, A. Tosetto, A. Tripodi, S. Siragusa, and C. Manotti Questions and answers on the use of dabigatran and prospectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Center (FCSA) Thromb. Haemost. 106 2011 868 876
11. A. Tripodi The laboratory and the direct oral anticoagulants Blood 121 2013 4032 4035
12. N.C. Chan, M. Coppens, J. Hirsh, J.S. Ginsberg, J.I. Weitz, T. Vanassche, J.D. Douketis, S. Schulman, and J.W. Eikelboom Real-world variability in dabigatran levels in patients with atrial fibrillation J. Thromb. Haemost. 13 2015 353 359
13. J. Douxfils, S. Lessire, A.S. Dincq, P. Hjemdahl, Y. Rönquist-Nii, A. Pohanka, M. Gourdin, B. Chatelain, J.M. Dogné, and F. Mullier Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays Thromb. Haemost. 30 113 2015 862 869
14. K.H. Liesenfeld, T. Lehr, C. Dansirikul, P.A. Reilly, S.J. Connolly, M.D. Ezekowitz, S. Yusuf, L. Wallentin, S. Haertter, and A. Staab Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial J. Thromb. Haemost. 9 2011 2168 2175
15. J. Stangier, and M. Feuring Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran Blood Coagul. Fibrinolysis 23 2012 138 143
16. M.M. Samama, J. Amiral, C. Guinet, E. Perzborn, and F. Depasse An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma Thromb. Haemost. 103 2010 815 825
17. CLSI User Verification of Precision and Estimation of Bias; Approved Guideline-Thrird Edition. CLSI Document EP15-A3 2014 Wayne, PA Clinical and Laboratory Standard Institute
18. P.A. Reilly, T. Lehr, S. Haertter, S.J. Connolly, S. Yusuf, J.W. Eikelboom, M.D. Ezekowitz, G. Nehmiz, S. Wang, L. Wallentin, and R.E.-L.Y. Investigators The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY trial (randomized evaluation of long-term anticoagulation therapy) J. Am. Coll. Cardiol. 63 2014 321 328
19. T. Hellwig, and M. Gusseth Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation Ann. Pharmacother. 47 2013 1478 1487